search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Development of a ¡°two hit¡± in vivo autologous platelet transfusion model in healthy volunteers


- candidate number26965
- NTR NumberNTR6493
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR28-mrt-2017
- Secondary IDsNL50117.018.14 METC AMC
- Public TitleDevelopment of a ¡°two hit¡± in vivo autologous platelet transfusion model in healthy volunteers
- Scientific TitleDevelopment of a ¡°two hit¡± in vivo autologous platelet transfusion model in healthy volunteers
- ACRONYMDIVA
- hypothesisIn the presence of a ¡°first hit¡± an aged apheresis platelet transfusion is able to induce a mild form of ALI
- Healt Condition(s) or Problem(s) studiedPlatelet therapy
- Inclusion criteria1)Healthy male volunteer
2)Age ¡Ý 18 years <35 years
- Exclusion criteria1)No informed consent
2)Any abnormal test result during the screening prior to inclusion of the study (medical history, physical examination, ECG, blood and urine examination, spirometry, DLCO measurement, chest x-ray).
3)History of drugs or alcohol abuse
4)Any present medication use on prescription
5)Smoking < 6 months
6)History of blood donation < 3 months
7)Blood loss of more 500 ml < 3 months
8)Previously transfused
9)Participation in any other medical drug study < 3 months
10)Participation in previous volunteer studies using LPS
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-apr-2017
- planned closingdate31-dec-2018
- Target number of participants36
- InterventionsAll subjects will be screened (medical history, physical examination, ECG, blood examination, spirometry, DLCO, chest x-ray) by the research physician of our hospital and of Sanquin Blood Bank prior to involvement in the experiment. All included healthy volunteers (n=36) will donate 1 unit of apheresis PLTs (approximately 150 - 400 ml). Processing and storage will be according to Sanquin Blood Bank protocol. Prior to transfusion, stored PLTs will be biotinylated to allow their identification by flow cytometry. In short, stored PLTs will be labelled with Sulfo-NHS biotine (5¦Ìg/ml). Subsequently on the study day healthy volunteers will receive a ¡°first hit¡± of either E. coli lipopolysaccharide (LPS) 2 ng/kg i.v. (n=18) or NaCl 0.9% 10 ml intraveneously ( n=18). Two hours after the ¡°first hit¡± the volunteers will receive an autologous transfusion of 1 unit of fresh (2 day storage) biotinylated PLTs or an autologous transfusion of 1 unit aged biotinylated (7 days of storage) PLTs or an equivalent volume of saline 0.9% infusion. The transfusion itself will be performed in 30-60 minutes. During the experiment subjects will be monitored for blood pressure and arterial oxygenation using an indwelling arterial line. Blood samples will be drawn from an indwelling artery line prior to the ¡°first hit¡±, prior to the transfusion, 10 minutes, 0,5, 1, 2, 4 and 6 hours after transfusion. Furthermore, 6 hours after transfusion spirometry and DLCO measurement will be repeated. A chest x-ray and a directed bronchoalveolar lavage (BAL) will be performed 6 hours after transfusion. In the BAL-fluid and plasma samples markers of inflammation, neutrophil activation and coagulation activation are measured to confirm whether we have developed a model of TRALI. Two days,four days and three months after the study day a venous sample of 4 ml will be collected to monitor platelet kinetics and to measure prevalence of biotin antibodies.
- Primary outcomeTest the hypothesis that in the presence of a ¡°first hit¡± an aged apheresis platelet transfusion is able to induce a mild form of ALI.
- Secondary outcome1)unravel several hypothesized inflammatory processes in the lungs of patients that develop TRALI (i.e., production of inflammatory mediators, neutrophil activation, complement activation, disturbed alveolar fibrin turnover).
2)assess the usefulness of several potential biomarkers of lung injury in TRALI (in particular recently proposed potential biomarkers, such as surfactant proteins, Clara cell protein, sRAGE and KL-6).
3)identify phenotypic changes of the transfused platelets and their interaction with other cell types in the receiver¡¯s circulation and their potential contribution to the development of lung injury.
4)Metabolic recovery of transfused thrombocytes after storage
- Timepoints1)Prior to experiment:
- Screening twice, at AMC and Sanquin
- Donating 1 unit of platelets 2or 7 days prior to experiment
2)Experiment day: subject will be admitted for one day at the intensive care
3)Follow up
- 2 days, 4 days and 3 months after experiment day
- Trial web site
- statusplanned
- CONTACT FOR PUBLIC QUERIES Sanne De Bruin
- CONTACT for SCIENTIFIC QUERIES Sanne De Bruin
- Sponsor/Initiator Academic Medical Center (AMC), Amsterdam
- Funding
(Source(s) of Monetary or Material Support)
Sanquin Blood Supply Foundation, Amsterdam, The Netherlands
- Publications
- Brief summaryTransfusion related acute long injury (TRALI) is the leading cause of transfusion related morbidity and mortality. TRALI is thought to be a ¡°two hit¡± event. The first event is the underlying condition of the patient, often sepsis or an infection, resulting in priming of neutrophils. The second event is the transfusion of a blood product. Additional research is needed to determine whether the use of fresh cell-containing blood products may be an additional measure to reduce TRALI.
The aim of this study is to develop a TRALI model in healthy volunteers. Subjects are extensively screened at the AMC and Sanquin (including medical history, physical examination, ECG, laboratory testing, spirometry and DLCO, X-thorax). If the subjects are enrolled in the study, they are randomized for the first hit in two groups, one receiving LPS 2ng/kg, the other group will receive saline. For the second hit the subjects are randomized between autologous fresh platelets (2 days old) and autologous stored platelets (7 days old). A small portion of the platelets will be biotinylated to identify the transfused platelets from the circulating population. 6 h after the transfusion spirometry, DLCO and X-thorax will be repeated and a broncho alveolar lavage will be performed to test whether the subjects did develop TRALI.
After transfusion multiple blood samples will be drawn to measure markers of inflammation, neutrophil activation and coagulation activation are measured to confirm whether we have developed a model of TRALI. Furthermore, biotinylated platelets will be isolated by flow cytometry to test metabolic recovery using liquid chromatography and mass spectrometry.
- Main changes (audit trail)
- RECORD28-mrt-2017 - 19-aug-2017


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl